Macitentan

Chemical formula: C₁₉H₂₀Br₂N₆O₄S  Molecular mass: 588.273 g/mol  PubChem compound: 16004692

Therapeutic indications

Macitentan is indicated for:

Pulmonary arterial hypertension functional class (FC) II to III

Population group: only adults (18 years old or older)

Macitentan, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.

Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Macitentan is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Severe hepatic impairment

Hepatic failure stage IV

Elevated baseline values of hepatic aminotransferases

at least one of
Hepatic failure stage IV
Alanine aminotransferase above reference range
Serum glutamic oxaloacetic transaminase level raised

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: OPSUMIT Film-coated tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈